Winner Medical(SZ:300888) Chang Jiang Shang Bao·2025-11-13 23:52Core Viewpoint - Company plans to invest approximately 2 billion yuan in a new production base for cotton non-woven fabric, marking a significant step in its vertical integration strategy aimed at enhancing supply chain control, cost management, and brand value [1][4][6]. Financial Health - As of September 2025, the company's debt-to-asset ratio stands at 33.87%, with total cash and investments around 6 billion yuan, and interest-bearing liabilities approximately 2.3 billion yuan [1][10]. - For the first three quarters of 2025, the company reported revenues of about 7.9 billion yuan and a net profit of 730 million yuan, both showing over 30% year-on-year growth [11][12]. Investment Details - The new production base will cover an area of about 1,000 acres and is expected to produce 20,000 tons of non-woven fabric annually, with the first phase set to commence production by September 2028 [4]. - The investment is part of the company's strategy to build a competitive moat and enhance its overall competitiveness and profitability [6]. R&D and Growth - The company has increased its R&D investment to 291 million yuan in the first three quarters of 2025, reflecting a year-on-year growth of 25.43% [2]. - The subsidiary, Purcotton, contributed over 50% of the company's revenue in the first half of 2025, achieving 2.75 billion yuan in revenue with a gross margin of 58.63% [5]. Strategic Expansion - The company has a history of aggressive acquisitions, including a 7.28 billion yuan purchase of a majority stake in Zhejiang Longtai Medical Technology in April 2022, enhancing its position in the high-end wound dressing market [9]. - Recent acquisitions have also included a 1.2 billion USD purchase of a majority stake in GRI, a global medical consumables company, to accelerate its international strategy [9].